Health Care [ 3/12 ] | Biotechnology [ 10/73 ]
NASDAQ | Common Stock
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California.
As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 25 | 0.00 Increased by +100.00% | -0.51 Increased by +100.00% |
| Aug 8, 25 | -0.71 Decreased by -47.92% | -0.50 Decreased by -42.00% |
| May 7, 25 | -0.49 Increased by +9.26% | -0.57 Increased by +13.29% |
| Feb 26, 25 | -1.02 Decreased by -104.00% | -0.76 Decreased by -34.32% |
| Nov 6, 24 | -1.39 Decreased by -208.89% | -0.64 Decreased by -117.19% |
| Aug 5, 24 | -0.48 Increased by +7.69% | -0.57 Increased by +15.79% |
| May 9, 24 | -0.54 Increased by 0.00% | -0.46 Decreased by -17.39% |
| Feb 29, 24 | -0.50 Decreased by -4.17% | -0.49 Decreased by -2.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -111.50 M Decreased by -132.44% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -71.28 M Decreased by -37.91% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 21.00 K Decreased by -91.03% | -118.35 M Decreased by -194.16% | Decreased by -563.59 K% Decreased by -3.18 K% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -149.07 M Decreased by -329.30% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -47.97 M Decreased by -24.95% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -51.68 M Increased by +38.56% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 234.00 K Increased by +N/A% | -40.23 M Decreased by -63.54% | Decreased by -17.19 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -34.73 M Decreased by -29.55% | Decreased by N/A% Decreased by N/A% |